We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+150.31%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
+$412M
Cap. Flow
+$25.7M
Cap. Flow %
2.41%
Top 10 Hldgs %
48.66%
Holding
270
New
60
Increased
70
Reduced
50
Closed
53

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$27.6M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$20.5M
3
ROIV icon
Roivant Sciences
ROIV
+$17.4M
4
ETNB
89bio
ETNB
+$12.6M
5
JANX icon
Janux Therapeutics
JANX
+$7.04M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$105M
2
PRTA icon
Prothena Corp
PRTA
+$14.6M
3
CGON icon
CG Oncology
CGON
+$7.97M
4
SAGE
Sage Therapeutics
SAGE
+$6.58M
5
VERV
Verve Therapeutics
VERV
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 83.19%
2 Financials 1.65%
3 Communication Services 0.09%
4 Consumer Discretionary 0.09%
5 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
76
DELISTED
Cidara Therapeutics
CDTX
$2.06M 0.19%
21,522
– –
RGNX icon
77
Regenxbio
RGNX
$708M
$1.98M 0.19%
205,409
-2,409
-1% -$21.3K
KRRO icon
78
Korro Bio
KRRO
$195M
$1.93M 0.18%
40,235
-28,580
-42% -$634K
RCKT icon
79
Rocket Pharmaceuticals
RCKT
$394M
$1.88M 0.18%
575,800
+300,000
+109% +$945K
OABI icon
80
OmniAb
OABI
$447M
$1.75M 0.16%
1,090,628
+764,520
+234% +$1.4M
ARWR icon
81
Arrowhead Research
ARWR
$12.4B
$1.72M 0.16%
49,800
-5,400
-10% -$119K
SLNO
82
DELISTED
Soleno Therapeutics
SLNO
$1.71M 0.16%
25,230
+7,900
+46% +$586K
DVAX
83
DELISTED
Dynavax Technologies
DVAX
$1.69M 0.16%
170,000
– –
ALKS icon
84
Alkermes
ALKS
$8.25B
$1.69M 0.16%
56,200
+11,200
+25% +$316K
GLUE icon
85
Monte Rosa Therapeutics
GLUE
$1.34B
$1.6M 0.15%
+215,752
New +$1.14M
MRK icon
86
Merck
MRK
$318B
$1.56M 0.15%
18,540
+11,500
+163% +$947K
CCIIU
87
Cohen Circle Acquisition Corp II Unit
CCIIU
$1.54M 0.14%
+150,000
New +$1.54M
ABOS icon
88
Acumen Pharmaceuticals
ABOS
$176M
$1.52M 0.14%
891,183
-25,000
-3% -$34.6K
XNCR icon
89
Xencor
XNCR
$1.55B
$1.51M 0.14%
128,865
+43,039
+50% +$374K
AGIO icon
90
Agios Pharmaceuticals
AGIO
$1.93B
$1.49M 0.14%
37,000
+1,100
+3% +$41.4K
WW
91
WW International
WW
$181M
$1.44M 0.13%
+52,450
New +$1.8M
ATXS
92
DELISTED
Astria Therapeutics
ATXS
$1.41M 0.13%
193,934
-55,712
-22% -$377K
CNTA
93
DELISTED
Centessa Pharmaceuticals
CNTA
$1.3M 0.12%
53,666
-243,100
-82% -$4.32M
QNCX icon
94
Quince Therapeutics
QNCX
$29.5M
$1.26M 0.12%
3,875
+3,160
+442% +$1.05M
PFE icon
95
Pfizer
PFE
$153B
$1.13M 0.11%
44,400
+5,000
+13% +$123K
MLTX icon
96
MoonLake Immunotherapeutics
MLTX
$1.55B
$1.09M 0.1%
151,495
+117,181
+341% +$6.11M
GRCE
97
Grace Therapeutics
GRCE
$34.7M
$1.04M 0.1%
350,450
+173,823
+98% +$545K
NUVL
98
DELISTED
Nuvalent
NUVL
$1.02M 0.1%
11,842
– –
BSAAU
99
BEST SPAC I Acquisition Corp Unit
BSAAU
$1.02M 0.1%
100,000
– –
EA
100
DELISTED
Electronic Arts
EA
$996K 0.09%
+4,936
New +$817K
2 3
4
5 6

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, ADAR1 Capital Management held 270 positions worth $1.06B, up 63% from $652M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

ADAR1 Capital Management's Q3 2025 filing shows 60 new, 70 increased, 50 reduced and 53 closed positions. Its largest new stake was Invivyd: 7,370,987 shares worth $8.11M. The largest sale was Abivax, an estimated $105M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.

  • ADAR1 Capital Management's largest Q3 2025 buy was Invivyd: 7,370,987 shares worth $8.11M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2025, an estimated $27.6M increase.
  • ADAR1 Capital Management's biggest Q3 2025 reduction was Abivax, cutting an estimated $105M.
  • ADAR1 Capital Management fully exited Sage Therapeutics in Q3 2025, selling an estimated $6.58M.
  • ADAR1 Capital Management's ten largest holdings make up 49% of its $1.06B portfolio in Q3 2025.
  • ADAR1 Capital Management opened 60 new positions and closed 53 in Q3 2025.
  • ADAR1 Capital Management's portfolio value rose 63% quarter-over-quarter to $1.06B.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.